Axsome therapeutics announces successful completion and results of phase 3 clinical program of axs-05 in alzheimer's disease agitation

Accord-2 phase 3 trial in alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)

AXS Ratings Summary

AXS Quant Ranking